Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends

Authors

Yun Qiu

Published

August 10, 2024

Abstract

Achieving long-term clinical remission in Crohn's disease (CD) with antitumor necrosis factor α (anti-TNF-α) agents remains challenging.

Supporters

Support the authors with ResearchCoin

Journal

Inflammatory Bowel Diseases

Topics

DOI

10.1093/ibd/izae176

Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends

Authors

Yun Qiu

Published

August 10, 2024

Abstract

Achieving long-term clinical remission in Crohn's disease (CD) with antitumor necrosis factor α (anti-TNF-α) agents remains challenging.

Supporters

Support the authors with ResearchCoin

Journal

Inflammatory Bowel Diseases

Topics

DOI

10.1093/ibd/izae176

Paper

Paper

Paper

Paper

Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends

Abstract

Supporters

Journal

Topics

DOI

Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends

Abstract

Supporters

Journal

Topics

DOI